Brief: Hls Therapeutics Reports Efficacy And Safety Results From Pilot Study Treating Covid-19 Infected Outpatients With Vascepa®
14/12/2020 11:33
Dec 14 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS REPORTS EFFICACY AND SAFETY RESULTS FROM
PILOT
STUDY TREATING COVID-19 INFECTED OUTPATIENTS WITH VASCEPA®
(ICOSAPENT ETHYL)
* HLS THERAPEUTICS INC - VASCEPA COVID-19 CARDIOLINK-9
RANDOMIZED
TRIAL SUGGESTS IMPROVEMENT IN PATIENT-REPORTED COVID-19 SYMPTOMS
* HLS THERAPEUTICS - VASCEPA ADMINISTRATION RESULTED IN
SIGNIFICANT 52% REDUCTION OF TOTAL PATIENT-REPORTED SYMPTOM
OUTCOME PREVALENCE SCORE
* HLS THERAPEUTICS - LARGER FOLLOW-ON CLINICAL STUDIES
COMMENCED
OF VASCEPA AS THERAPEUTIC OPTION IN COVID-19 SETTINGS,
ANTICIPATED TO BE COMPLETED IN 2021
Source text for Eikon: ID:nCNWTphfza
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease